enGene Holdings Inc. (ENGN)
| Previous close | 15.74 |
| Open | 15.34 |
| Bid | 13.02 x 100 |
| Ask | 0.00 x 0 |
| Day's range | 13.49 - 15.41 |
| 52-week range | 6.69 - 47.17 |
| Volume | |
| Avg. volume | 50,851 |
| Market cap | 617.547M |
| Beta (5Y monthly) | -0.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 35.50 |
PR Newswire/C O R R E C T I O N -- enGene Inc./
enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that Raj Pruthi MD MHA FACS has joined the Company as SVP, Urologic Oncology and Clinical Development, reporting to enGene's Chief Medical Officer, Dr. Richard Bryce. In this role, Dr. Pruthi's responsibilities will include sup
PR NewswireenGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress
enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced its financial results for the first quarter ended January 31, 2024.
PR NewswireenGene To Present at the Leerink Partners Global Biopharma Conference
enGene Holdings Inc. (Nasdaq: ENGN) or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that Jason Hanson, Chief Executive Officer, will present at the Leerink Partners Global Biopharma Conference in Miami, FL on March 13, 2024, at 8:40 a.m. ET.
